Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations.
Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004.
was also responsible for clinical development at Argenta from 2008 to 2010.
Previously, Dr. Fitzgerald
was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology.
She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.
has spent over 20 years in the pharmaceutical industry and her
major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis.
is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma.
is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.